JP2021502363A - 早期産児における粘膜抵抗力および腸／肺機能の成熟 - Google Patents

早期産児における粘膜抵抗力および腸／肺機能の成熟 Download PDF

Info

Publication number
JP2021502363A
JP2021502363A JP2020524879A JP2020524879A JP2021502363A JP 2021502363 A JP2021502363 A JP 2021502363A JP 2020524879 A JP2020524879 A JP 2020524879A JP 2020524879 A JP2020524879 A JP 2020524879A JP 2021502363 A JP2021502363 A JP 2021502363A
Authority
JP
Japan
Prior art keywords
defensin
hbd
lactoferrin
defensins
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502363A5 (https=
Inventor
ノーキルド，ペーター
Original Assignee
ディフェンシン セラピューティクス エーピーエス
ディフェンシン セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディフェンシン セラピューティクス エーピーエス, ディフェンシン セラピューティクス エーピーエス filed Critical ディフェンシン セラピューティクス エーピーエス
Publication of JP2021502363A publication Critical patent/JP2021502363A/ja
Publication of JP2021502363A5 publication Critical patent/JP2021502363A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020524879A 2017-11-10 2018-11-09 早期産児における粘膜抵抗力および腸／肺機能の成熟 Pending JP2021502363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17201002 2017-11-10
EP17201002.7 2017-11-10
PCT/EP2018/080814 WO2019092201A2 (en) 2017-11-10 2018-11-09 Maturation of mucosal defense and gut/lung function in the preterm infant

Publications (2)

Publication Number Publication Date
JP2021502363A true JP2021502363A (ja) 2021-01-28
JP2021502363A5 JP2021502363A5 (https=) 2021-12-23

Family

ID=60301879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524879A Pending JP2021502363A (ja) 2017-11-10 2018-11-09 早期産児における粘膜抵抗力および腸／肺機能の成熟

Country Status (13)

Country Link
US (2) US20200316172A1 (https=)
EP (1) EP3706773A2 (https=)
JP (1) JP2021502363A (https=)
KR (1) KR20200095472A (https=)
CN (1) CN111556759A (https=)
AU (1) AU2018363783A1 (https=)
BR (1) BR112020009254A2 (https=)
CA (1) CA3082288A1 (https=)
MX (1) MX2020004863A (https=)
RU (1) RU2020115758A (https=)
SG (1) SG11202003868UA (https=)
WO (1) WO2019092201A2 (https=)
ZA (1) ZA202002992B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006848A (es) * 2016-12-13 2019-10-07 Defensin Therapeutics Aps Metodos para tratar condiciones inflamatorias de los pulmones.
PL3713590T3 (pl) * 2017-11-24 2025-09-15 Defensin Therapeutics Aps Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
CN114903973B (zh) * 2022-04-21 2025-08-29 上海市肺科医院 一种呼吸道粘膜免疫增强药物组合物
US20240252558A1 (en) * 2023-01-29 2024-08-01 The University Of Chicago Probiotics to rescue maternal immune activation-induced neurodevelopment deficits
KR20240150943A (ko) 2023-04-10 2024-10-17 (주)인트젠 영유아용 유산균 프로바이오틱스 조성물
CN116868958A (zh) * 2023-09-06 2023-10-13 中国人民解放军军事科学院军事医学研究院 构建缺氧导致肠道应激损伤的动物模型的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517389A (ja) * 2002-10-14 2006-07-27 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２化合物、製剤、及びそれらの使用
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
JP2012510800A (ja) * 2008-12-05 2012-05-17 ネステク ソシエテ アノニム 低出生体重児において使用するための組成物
JP2014523906A (ja) * 2011-07-08 2014-09-18 ディフェンシン セラピューティクス アンパルトセルスカブ 炎症性腸疾患の経口治療
JP2015514481A (ja) * 2012-04-23 2015-05-21 チエシイ ファルマセウティシ ソシエタ ペル アチオニＣｈｉｅｓｉ Ｆａｒｍａｃｅｕｔｉｃｉ Ｓ．Ｐ．Ａ． 噴霧化による肺サーファクタントの投与方法及びシステム
WO2017129195A1 (en) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
WO2018108971A2 (en) * 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG172709A1 (en) * 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
EA201200416A1 (ru) * 2012-03-12 2013-09-30 Аделя Сабир кызы Гаджиева Способ ранней диагностики и лечения некротического энтероколита у новорожденных
EP2968073B1 (en) * 2013-03-13 2017-08-16 Rush University Medical Center Delivery device for oropharyngeal administration of mother's colostrum and milk

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517389A (ja) * 2002-10-14 2006-07-27 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２化合物、製剤、及びそれらの使用
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
JP2012510800A (ja) * 2008-12-05 2012-05-17 ネステク ソシエテ アノニム 低出生体重児において使用するための組成物
JP2014523906A (ja) * 2011-07-08 2014-09-18 ディフェンシン セラピューティクス アンパルトセルスカブ 炎症性腸疾患の経口治療
JP2015514481A (ja) * 2012-04-23 2015-05-21 チエシイ ファルマセウティシ ソシエタ ペル アチオニＣｈｉｅｓｉ Ｆａｒｍａｃｅｕｔｉｃｉ Ｓ．Ｐ．Ａ． 噴霧化による肺サーファクタントの投与方法及びシステム
WO2017129195A1 (en) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota
WO2018108971A2 (en) * 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF NUTRITION, vol. 115, JPN6023000200, 2016, pages 1178 - 1193, ISSN: 0005118868 *
NEONATAL CARE, vol. 27(3), JPN6023000199, 2014, pages 284 - 286, ISSN: 0005118867 *

Also Published As

Publication number Publication date
CN111556759A (zh) 2020-08-18
BR112020009254A2 (pt) 2020-10-27
KR20200095472A (ko) 2020-08-10
MX2020004863A (es) 2020-10-14
US20250009844A1 (en) 2025-01-09
WO2019092201A3 (en) 2019-06-27
ZA202002992B (en) 2021-10-27
RU2020115758A (ru) 2021-12-10
CA3082288A1 (en) 2019-05-16
SG11202003868UA (en) 2020-05-28
US20200316172A1 (en) 2020-10-08
EP3706773A2 (en) 2020-09-16
WO2019092201A2 (en) 2019-05-16
AU2018363783A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
Zimecki et al. Milk-derived proteins and peptides of potential therapeutic and nutritive value.
CN112004549B (zh) 用于保护氧敏感革兰氏阳性菌的REG3α
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
Avalos-Gómez et al. Lactoferrin: An effective weapon in the battle against bacterial infections
EP1228097B1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
US20250145674A1 (en) Novel Protein, and Therapeutic and Cosmetic Uses Thereof
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
US20160000875A1 (en) Gm-csf for treatment of chronic oral mucositis
US7060677B1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801